L. Smith

发表

Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys

P. Jenner, R. Pearce, H. Kase, 1998, Annals of neurology.

Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease

P. Jenner, Joanna Iczkiewicz, S. Rose, 2006, Brain Research.

A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets

E. Syed, P. Jenner, L. Johnston, 2005, The European journal of neuroscience.

3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates

P. Jenner, M. Kuoppamäki, M. Iravani, 2003, The Journal of Neuroscience.

Transdermal Administration of Piribedil Reverses MPTP-induced Motor Deficits in the Common Marmoset

C. Bonhomme, P. Jenner, R. Pearce, 2000, Clinical neuropharmacology.

An appraisal of the antiparkinsonian activity of piribedil in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmosets

P. Jenner, C. Marsden, Lance A. Smith, 1996, Movement disorders : official journal of the Movement Disorder Society.

Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets

J. Hagan, P. Jenner, R. Pearce, 2004, Pharmacology, Biochemistry and Behavior.

Combined Use of the Adenosine A2A Antagonist KW-6002 with l -DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys

P. Jenner, R. Pearce, H. Kase, 2000, Experimental Neurology.

Dopamine, but Not Norepinephrine or Serotonin, Reuptake Inhibition Reverses Motor Deficits in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates

P. Jenner, S. Cheetham, Matthew J Hansard, 2002, Journal of Pharmacology and Experimental Therapeutics.

Proteomic Analysis of Striatum from MPTP-Treated Marmosets (Callithrix jacchus) with l-DOPA-Induced Dyskinesia of Differing Severity

P. Jenner, S. Rose, M. Jackson, 2014, Journal of Molecular Neuroscience.

The dopamine D2 receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with l-dopa

J. Kehne, D. Hoffman, P. Jenner, 2009, Journal of Neural Transmission.

The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP‐treated primates

P. Jenner, S. Cheetham, M. Jackson, 2004, Movement disorders : official journal of the Movement Disorder Society.

The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP‐treated and levodopa‐primed common marmosets

J. Scheel-Krüger, P. Jenner, R. Pearce, 2002, Movement disorders : official journal of the Movement Disorder Society.

Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure

P. Jenner, Lance A Smith, Michael J Jackson, 2003, Movement disorders : official journal of the Movement Disorder Society.

Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset

C. Marsden, A. Hunter, P. Jenner, 1995, Psychopharmacology.

Switching from Levodopa to the Long-acting Dopamine D2/D3 Agonist Piribedil Reduces the Expression of Dyskinesia While Maintaining Effective Motor Activity in MPTP-treated Primates

S. Del Signore, P. Jenner, S. Rose, 2006, Clinical neuropharmacology.

Repeated administration of piribedil induces less dyskinesia than L‐dopa in MPTP‐treated common marmosets: A behavioural and biochemical investigation

C. Bonhomme, S. Del Signore, P. Jenner, 2002, Movement disorders : official journal of the Movement Disorder Society.

The administration of entacapone prevents l-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates

P. Jenner, W. Olanow, S. Rose, 2007, Experimental Neurology.

The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.

P. Jenner, S. Rose, P. Carminati, 2006, European journal of pharmacology.

Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease

J. Kemp, T. Klockgether, U. Wüllner, 2004, Experimental Neurology.

Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets

P. Jenner, S. Rose, M. Jackson, 2007, Experimental Neurology.

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates

P. Jenner, W. Olanow, S. Rose, 2005, Movement disorders : official journal of the Movement Disorder Society.

Alterations in striatal and extrastriatal D‐1 and D‐2 dopamine receptors in the MPTP‐treated common marmoset: An autoradiographic study

C D Marsden, A. Hunter, P. Jenner, 1993, Synapse.

Beginning‐of‐dose and rebound worsening in MPTP‐treated common marmosets treated with levodopa

N. Quinn, P. Jenner, B. Zeng, 2002, Movement disorders : official journal of the Movement Disorder Society.

Striatal leucine‐rich repeat kinase 2 mRNA is increased in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned common marmosets (Callithrix jacchus) with l‐3, 4‐dihydroxyphenylalanine methyl ester‐induced dyskinesia

P. Jenner, S. Rose, M. Jackson, 2007, The European journal of neuroscience.

Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP‐treated common marmosets

P. Jenner, S. Rose, M. Jackson, 2005, The European journal of neuroscience.

Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets

K. Lange, P. Jenner, P. Löschmann, 2005, Psychopharmacology.

Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets

C. Marsden, K. Lange, P. Jähnig, 2005, Psychopharmacology.

S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole

M. Millan, J. Brotchie, A. Gobert, 2004, Journal of Pharmacology and Experimental Therapeutics.

Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets

A. Lees, R. Katzenschlager, P. Jenner, 2007, Movement disorders : official journal of the Movement Disorder Society.

Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus)

P. Jenner, R. Pearce, L. Smith, 1995, Movement disorders : official journal of the Movement Disorder Society.

Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates.

P. Jenner, S. Cheetham, M. Jackson, 2002, European journal of pharmacology.

Endogenous dopaminergic tone and dopamine agonist action

P. Jenner, L. Smith, S. Treseder, 2000, Movement disorders : official journal of the Movement Disorder Society.

A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.

J. Kebabian, P. Jenner, M. Williams, 1992, European journal of pharmacology.